Impact Factor 3.845 | CiteScore 3.92
More on impact ›

Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Pharmacol. | doi: 10.3389/fphar.2019.01393

Histone Methyltransferases as Therapeutic Targets for Kidney Diseases

  • 1Department of Nephrology, Shanghai East Hospital, Tongji University School of Medicine, China
  • 2Brown University, United States

Emerging evidence has demonstrated that epigenetic regulation plays a vital role in gene expression under normal and pathological conditions. Alterations in the expression of histone methyltransferases have been reported to be associated with multiple kidney diseases, including acute kidney injury, chronic kidney disease, diabetic Nephropathy, polycystic kidney disease, and renal cell carcinoma. In this review, we summarize recent knowledge of expression and activation of various histone methyltransferases and their functional roles in kidney diseases. We also provide new insights into the pathogenesis of epigenetic regulation involved in the development of kidney diseases.

Keywords: chronic kidney diseases,, Epigenetic regulations, histone modification, histone methyltransferase, Expression

Received: 06 May 2019; Accepted: 31 Oct 2019.

Copyright: © 2019 Yu and Zhuang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Shougang Zhuang, Brown University, Providence, United States,